CEConversations
Episodes
47 episodes
A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC
Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, par...
Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies
Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care rema...
Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which...
Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of ongoing treatment continues ...
The New Era of Hemophilia Treatment
We explore how new non‑factor options and high‑sustained factor products are changing hemophilia care and why shared decision making leads to better, more flexible lives. We connect treatment choice to joint health, mental health, aging, and ev...
MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexif...
Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies
| Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often l...
The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations
| Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein k...
Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present t...
Treating Metastatic HER2-negative Breast Cancer: Oncology Nursing Approaches to Improve Patient Quality of Life
In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the management of AEs associated...
Advancing Cervical Cancer Care: Navigating New Therapies, Guidelines, and Patient-Centric Approaches
In this CE Concepts Grand Rounds series, expert faculty will examine the evolving treatment landscape for advanced cervical cancer and discuss how they develop individualized treatment plans that apply current guideline recommendations, conside...
MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-World Applications in NF1-PN Management
In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients;...
All Hands on Deck: Spotlight on Clinical Advances in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and...
Advancements in the Management of Relapsed/Refractory B-Cell Malignancies – Integrating Recent Data into Practice to Improve Outcomes
In this CE Concepts Grand Rounds podcast, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing tre...
All Hands on Deck: A Focus on Current and Emerging Treatment Options in the Frontline Setting for Peripheral T-cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance t...
All Hands on Deck in Cervical Cancer Care: Screening, Treatment, and Equity Strategies to Improve Patient Lives
The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with ...
All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, com...
Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial data for ...
Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer
Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients...
Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies
Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel th...
Navigating New Waters for Advanced or Recurrent Endometrial Cancer
Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifie...
Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation
Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs). Advances in cancer treatments and the resulting improvements in patient survival ...
Actionable Strategies in Community Oncology to Achieve Equity in Triple-Negative Breast Cancer
This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our facult...
Primary Care Perspectives on Obesity: Embracing Novel Agents to Optimize Patient Outcomes
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www...
Meeting Complex Challenges in Proteinuric Glomerular Disease: An Expert Review of Emerging Data and Novel Therapeutics for IgA Nephropathy
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/igan-ee-podcastThis activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular ...